# Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery

> **NCT01612910** · PHASE2 · WITHDRAWN · sponsor: **Barbara Ann Karmanos Cancer Institute**

## Conditions studied

- Breast Cancer Female

## Interventions

- **DRUG:** oral microencapsulated diindolylmethane
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01612910
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-06
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Research cancelled.
- **Last updated:** 2014-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01612910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01612910, "Oral Microencapsulated Diindolylmethane in Treating Patients With Stage II-III Triple Negative, Androgen Receptor Positive Breast Cancer Who Have Undergone Chemotherapy and Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01612910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*